2024-09-28 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis:

**Company Overview:** Abbott Laboratories is a global healthcare company that develops, manufactures, and sells a wide range of medical devices, pharmaceuticals, and nutritional products. 

**Performance Analysis:**

**1.  Performance vs S&P 500:**

   * ABT's cumulative return is 102.31% compared to the S&P 500's 134.22%. 
   * The current price difference is -31.91%, which places it at the 11.23% percentile of historical performance compared to the S&P 500.

**2.  Recent Price Movement:**

   * Closing Price: 112.73
   * 5-day Moving Average: 113.51
   * 20-day Moving Average: 114.83
   * 60-day Moving Average: 109.77

   **Analysis:** The stock is currently trading below its 5-day, 20-day, and 60-day moving averages, indicating a short-term downtrend.

**3.  Technical Indicators:**

   * RSI: 45.78 -  This suggests that the stock is in a neutral territory, neither overbought nor oversold.
   * PPO: -0.58 -  The PPO is negative, which suggests a bearish trend.
   * Delta_Previous_Relative_Divergence: -5.19 -  Indicates a recent short-term price decline relative to the S&P 500.
   * Expected Return: 0.0% -  The expected return over a 5-year period is estimated to be 0%. 

   **Analysis:** The technical indicators are mixed, with some signals suggesting a potential downturn in the short term.

**4.  Recent Earnings and Outlook:**

| Date       | EPS   | Revenue  |
|------------|-------|----------|
| 2024-07-31 | 0.74  | 10.38 B$ |
| 2024-05-02 | 0.70  | 9.96 B$ |
| 2023-11-01 | 0.82  | 10.14 B$ |
| 2023-08-03 | 0.79  | 9.98 B$ |
| 2023-07-31 | 0.79  | 9.98 B$ |

**Analysis:** The most recent earnings report for Q2 2024, released on July 31st, showed EPS of $0.74, exceeding analysts' estimates of $0.69. Revenue of $10.38 billion also surpassed expectations. Abbott Laboratories continues to demonstrate steady growth in revenue and profitability.

**5. News & Recent Issues:**

* **Recent Market Outlook:**  Analysts are generally optimistic about Abbott Laboratories' long-term prospects, citing its diversified portfolio, strong brand recognition, and consistent financial performance. 
* **Analyst Opinions:** The stock currently holds a "Hold" rating from analysts, with a consensus price target of $120.
* **Performance Highlights:** Abbott Laboratories has historically been a reliable dividend payer, with a strong track record of increasing its dividend annually.

**6.  Overall Analysis:**

Abbott Laboratories is a well-established healthcare company with a diversified portfolio and a consistent history of profitability. While the stock's recent price movement has been somewhat lackluster, the company's strong financial performance and positive outlook suggest potential for future growth. The current technical indicators are mixed, but with earnings exceeding expectations and positive analyst sentiment, ABT might be a good consideration for long-term investors seeking a stable and reliable healthcare investment. 

**7. Disclaimer:** This analysis is for informational purposes only and should not be considered as financial advice. Investment decisions should be made based on your own research and consultation with a qualified financial advisor. 
